Delivery Order SPE2DB25D9320-SPE2DB25FWFBS
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,311.35 by the Defense Logistics Agency on July 18, 2025, for the supply of Xtandi 40 mg capsules (120-count). The delivery order carries an ultimate completion date of July 21, 2025, and does not utilize a set-aside designation. This award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $77,604.30 firm fixed-price delivery order is for the supply of 120 units of the prescription drug Xtandi 40 mg capsules, with a completion date of March 9, 2023. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract, valued at $12,934.05, to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Xtandi 40 mg capsules. DMS Pharmaceutical Group holds an Indefinite Delivery Vehicle (IDV) contract, valued up to $4,999,999, with DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders for a broad range of pharmaceutical...
- This federal contract award was issued by the Medical Supply Chain division of the Defense agency to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $4,311.35 firm fixed-price delivery order is for the supply of 120 capsules of the drug Xtandi 40 mg. The contract has an ultimate completion date of May 13, 2025. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA)...
- This federal contract award is a $4,311.35 firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 120 capsules of the prescription drug Xtandi (40 mg) with a completion date of May 20, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,311.35 contract is for the delivery of 120 capsules of the medication Xtandi 40 mg. The contract has an ultimate completion date of June 27, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
- The Defense Logistics Agency (DLA) awarded a $4,311.35 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which covers a wide range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications,...
- This is a $8,622.72 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order is for the supply of 120 capsules of the prescription drug Xtandi 40 mg and has a completion date of November 7, 2024. DMS Pharmaceutical Group Inc. holds a single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, for the delivery of 120 capsules of the drug Xtandi (40 mg) with a potential value of $25,868.10. This order is part of a larger single-award indefinite delivery vehicle (IDV) contract, worth up to $4,999,999, that DMS Pharmaceutical Group holds with DLA to provide a range of branded and generic pharmaceutical products to fulfill the recurring...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of 120 count bottles of the prescription drug Xtandi 40 mg capsules. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program,...
- SPE2DB25D9320Indefinite Delivery Contract
- SPE2DB25D9320-SPE2DB25FWFBSDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $4,311.35 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on July 18, 2025, for 120 capsules of Xtandi 40 mg. The delivery order is not designated as a set-aside contract and carries an ultimate completion date of July 21, 2025. This award represents a single delivery transaction executed under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.9 billion contract vehicle through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group specializes in distributing branded and generic prescription medications, biologics, and medical consumables to Department of Defense healthcare facilities nationwide. Xtandi, an oncology treatment, exemplifies the specialized pharmaceutical products the company routinely delivers through its DLA contract portfolio. The company's established federal procurement history and status as a woman-owned small business have positioned it as a consistent performer in securing delivery orders for high-value medications and specialty pharmaceuticals supporting military health system requirements across multiple therapeutic categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 7/18/25 |